FLT-190

N/A

Report date: 2023/10/26 16:47:14

Base Information

Drug NameFLT-190
Drug Alias NameFLT190 AAV gene therapyFT-190FLT-190
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVS3 vector
Mechanisms of ActionGene transferenceα-Galactosidase stimulants
Targetsα-Galactosidase
Therapy Area/IndicationsLysosomal Storage DiseasesFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNorway +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSpur Therapeutics
Active IndicationsN/A
Inactive IndicationsLysosomal Storage DiseasesFabry Disease

Other Information

ATC CodeN/A
Related LinksN/A